Zarir Farokh Udwadia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zarir Farokh Udwadia has a total of 238 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey A. Tornheim
Center for Infectious Diseases in India, Division of Infectious Diseases Johns Hopkins University School of Medicine Baltimore Maryland USA
4 shared publications - 4 Lia D’aMbrosio
Public Health Consulting Group, Lugano, Switzerland
3 shared publications Camilla Rodrigues
Department of Microbiology, P. D. Hinduja National Hospital and Medical Research Centre, Mumbai, Maharashtra, India
3 shared publications- Giovanni Battista Migliori
Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy
3 shared publications - Giovanni Sotgiu
Clinical Epidemiology and Medical Statistics Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy
3 shared publications - Mahamadou Bassirou Souleymane
Damien Foundation, Niamey, Niger
3 shared publications
Latest Publications
- 14 May 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (4) , e710
The Madras Trial and Tuberculosis Sanatoria
- 14 May 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (4) , e710
The Madras Trial and Tuberculosis Sanatoria
- 19 November 2024
- Published by Elsevier in Indian Journal of Tuberculosis
- Vol. 72 (3) , 282
Nikshay Poshan Yojana for all TB patients: Difficulties in access for multidrug-resistant TB patients
- 19 November 2024
- Published by Elsevier in Indian Journal of Tuberculosis
- Vol. 72 (3) , 282
Nikshay Poshan Yojana for all TB patients: Difficulties in access for multidrug-resistant TB patients
- Open Access
- 23 July 2024
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 50 (3) , e20240077
Impact of COVID-19 on diagnosis of tuberculosis and tuberculosis infection in South America, Asia, and Africa
- 23 July 2024
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 50 (3) , e20240077
Open AccessImpact of COVID-19 on diagnosis of tuberculosis and tuberculosis infection in South America, Asia, and Africa
- Open Access
- 28 August 2023
- Published by Medknow in Lung India
- Vol. 40 (5) , 404-405
Treating household contacts of MDR-TB patients: Are we being too hasty?
- 28 August 2023
- Published by Medknow in Lung India
- Vol. 40 (5) , 404-405
Open AccessTreating household contacts of MDR-TB patients: Are we being too hasty?
- Open Access
- 28 April 2023
- Published by Medknow in Lung India
- Vol. 40 (3) , 290-291
Swimming against the STREAM: Why STREAM 2 data cannot be easily applied to MDR-TB patients across India
- 28 April 2023
- Published by Medknow in Lung India
- Vol. 40 (3) , 290-291
Open AccessSwimming against the STREAM: Why STREAM 2 data cannot be easily applied to MDR-TB patients across India
- Open Access
- 1 March 2023
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 13 (1) , 44-49
COVID-19 in the Asia Pacific: Impact on climate change, allergic diseases and One Health
Climate change and environmental factors such as air pollution and loss of biodiversity are known to have a major impact not only on allergic diseases but also on many noncommunicable diseases. Coronavirus disease 2019 (COVID-19) resulted in many environmental changes during the different phases of the pandemic. The use of face masks, enhanced hand hygiene with hand rubs and sanitizers, use of personal protective equipment (gowns and gloves), and safe-distancing measures, reduced the overall incidence of respiratory infections and other communicable diseases. Lockdowns and border closures resulted in a significant reduction in vehicular traffic and hence environmental air pollution. Paradoxically, the use of personal protective equipment and disposables contributed to an increase in environmental waste disposal and new problems such as occupational dermatoses, especially among healthcare workers. Environmental changes and climate change over time may impact the exposome, genome, and microbiome, with the potential for short- and long-term effects on the incidence and prevalence of the allergic disease. The constant use and access to mobile digital devices and technology disrupt work–life harmony and mental well-being. The complex interactions between the environment, genetics, immune, and neuroendocrine systems may have short- and long-term impact on the risk and development of allergic and immunologic diseases in the future.
- 1 March 2023
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 13 (1) , 44-49
Open AccessCOVID-19 in the Asia Pacific: Impact on climate change, allergic diseases and One Health
Climate change and environmental factors such as air pollution and loss of biodiversity are known to have a major impact not only on allergic diseases but also on many noncommunicable diseases. Coronavirus disease 2019 (COVID-19) resulted in many environmental changes during the different phases of the pandemic. The use of face masks, enhanced hand hygiene with hand rubs and sanitizers, use of personal protective equipment (gowns and gloves), and safe-distancing measures, reduced the overall incidence of respiratory infections and other communicable diseases. Lockdowns and border closures resulted in a significant reduction in vehicular traffic and hence environmental air pollution. Paradoxically, the use of personal protective equipment and disposables contributed to an increase in environmental waste disposal and new problems such as occupational dermatoses, especially among healthcare workers. Environmental changes and climate change over time may impact the exposome, genome, and microbiome, with the potential for short- and long-term effects on the incidence and prevalence of the allergic disease. The constant use and access to mobile digital devices and technology disrupt work–life harmony and mental well-being. The complex interactions between the environment, genetics, immune, and neuroendocrine systems may have short- and long-term impact on the risk and development of allergic and immunologic diseases in the future.
- Open Access
- 1 March 2023
- Published by Wolters Kluwer Health
- Vol. 13 (1) , 44-49
COVID-19 in the Asia Pacific: Impact on climate change, allergic diseases and One Health
Climate change and environmental factors such as air pollution and loss of biodiversity are known to have a major impact not only on allergic diseases but also on many noncommunicable diseases. Coronavirus disease 2019 (COVID-19) resulted in many environmental changes during the different phases of the pandemic. The use of face masks, enhanced hand hygiene with hand rubs and sanitizers, use of personal protective equipment (gowns and gloves), and safe-distancing measures, reduced the overall incidence of respiratory infections and other communicable diseases. Lockdowns and border closures resulted in a significant reduction in vehicular traffic and hence environmental air pollution. Paradoxically, the use of personal protective equipment and disposables contributed to an increase in environmental waste disposal and new problems such as occupational dermatoses, especially among healthcare workers. Environmental changes and climate change over time may impact the exposome, genome, and microbiome, with the potential for short- and long-term effects on the incidence and prevalence of the allergic disease. The constant use and access to mobile digital devices and technology disrupt work-life harmony and mental well-being. The complex interactions between the environment, genetics, immune, and neuroendocrine systems may have short- and long-term impact on the risk and development of allergic and immunologic diseases in the future.
- 1 March 2023
- Published by Wolters Kluwer Health
- Vol. 13 (1) , 44-49
Open AccessCOVID-19 in the Asia Pacific: Impact on climate change, allergic diseases and One Health
Climate change and environmental factors such as air pollution and loss of biodiversity are known to have a major impact not only on allergic diseases but also on many noncommunicable diseases. Coronavirus disease 2019 (COVID-19) resulted in many environmental changes during the different phases of the pandemic. The use of face masks, enhanced hand hygiene with hand rubs and sanitizers, use of personal protective equipment (gowns and gloves), and safe-distancing measures, reduced the overall incidence of respiratory infections and other communicable diseases. Lockdowns and border closures resulted in a significant reduction in vehicular traffic and hence environmental air pollution. Paradoxically, the use of personal protective equipment and disposables contributed to an increase in environmental waste disposal and new problems such as occupational dermatoses, especially among healthcare workers. Environmental changes and climate change over time may impact the exposome, genome, and microbiome, with the potential for short- and long-term effects on the incidence and prevalence of the allergic disease. The constant use and access to mobile digital devices and technology disrupt work-life harmony and mental well-being. The complex interactions between the environment, genetics, immune, and neuroendocrine systems may have short- and long-term impact on the risk and development of allergic and immunologic diseases in the future.
- Open Access
- 30 November 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (23) , 7132
Prognosis of Spontaneous Pneumothorax/Pneumomediastinum in Coronavirus Disease 2019: The CoBiF Score
Objectives: Pneumothorax and pneumomediastinum are associated with high mortality in invasively ventilated coronavirus disease 2019 (COVID-19) patients; however, the mortality rates among non-intubated patients remain unknown. We aimed to analyze the clinical features of COVID-19-associated pneumothorax/pneumomediastinum in non-intubated patients and identify risk factors for mortality. Methods: We searched PubMed Scopus and Embase from January 2020 to December 2021. We performed a pooled analysis of 151 patients with no invasive mechanical ventilation history from 17 case series and 87 case reports. Subsequently, we developed a novel scoring system to predict in-hospital mortality; the system was further validated in multinational cohorts from ten countries (n = 133). Results: Clinical scenarios included pneumothorax/pneumomediastinum at presentation (n = 68), pneumothorax/pneumomediastinum onset during hospitalization (n = 65), and pneumothorax/pneumomediastinum development after recent COVID-19 treatment (n = 18). Significant differences were not observed in clinical outcomes between patients with pneumomediastinum and pneumothorax (±pneumomediastinum). The overall mortality rate of pneumothorax/pneumomediastinum was 23.2%. Risk factor analysis revealed that comorbidities bilateral pneumothorax and fever at pneumothorax/pneumomediastinum presentation were predictors for mortality. In the new scoring system, i.e., the CoBiF system, the area under the curve which was used to assess the predictability of mortality was 0.887. External validation results were also promising (area under the curve: 0.709). Conclusions: The presence of comorbidity bilateral pneumothorax and fever on presentation are significantly associated with poor prognosis in COVID-19 patients with spontaneous pneumothorax/pneumomediastinum. The CoBiF score can predict mortality in clinical settings as well as simplify the identification and appropriate management of patients at high risk.
- 30 November 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (23) , 7132
Open AccessPrognosis of Spontaneous Pneumothorax/Pneumomediastinum in Coronavirus Disease 2019: The CoBiF Score
Objectives: Pneumothorax and pneumomediastinum are associated with high mortality in invasively ventilated coronavirus disease 2019 (COVID-19) patients; however, the mortality rates among non-intubated patients remain unknown. We aimed to analyze the clinical features of COVID-19-associated pneumothorax/pneumomediastinum in non-intubated patients and identify risk factors for mortality. Methods: We searched PubMed Scopus and Embase from January 2020 to December 2021. We performed a pooled analysis of 151 patients with no invasive mechanical ventilation history from 17 case series and 87 case reports. Subsequently, we developed a novel scoring system to predict in-hospital mortality; the system was further validated in multinational cohorts from ten countries (n = 133). Results: Clinical scenarios included pneumothorax/pneumomediastinum at presentation (n = 68), pneumothorax/pneumomediastinum onset during hospitalization (n = 65), and pneumothorax/pneumomediastinum development after recent COVID-19 treatment (n = 18). Significant differences were not observed in clinical outcomes between patients with pneumomediastinum and pneumothorax (±pneumomediastinum). The overall mortality rate of pneumothorax/pneumomediastinum was 23.2%. Risk factor analysis revealed that comorbidities bilateral pneumothorax and fever at pneumothorax/pneumomediastinum presentation were predictors for mortality. In the new scoring system, i.e., the CoBiF system, the area under the curve which was used to assess the predictability of mortality was 0.887. External validation results were also promising (area under the curve: 0.709). Conclusions: The presence of comorbidity bilateral pneumothorax and fever on presentation are significantly associated with poor prognosis in COVID-19 patients with spontaneous pneumothorax/pneumomediastinum. The CoBiF score can predict mortality in clinical settings as well as simplify the identification and appropriate management of patients at high risk.
- Open Access
- 1 November 2022
- Published by Medknow in Lung India
- Vol. 39 (6) , 587-588
Severe interstitial lung disease persisting 2 years post-COVID-19 despite anti-fibrotic therapy
- 1 November 2022
- Published by Medknow in Lung India
- Vol. 39 (6) , 587-588
Open AccessSevere interstitial lung disease persisting 2 years post-COVID-19 despite anti-fibrotic therapy
- Open Access
- 30 April 2022
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 48 (2) , e20220087
Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study
The objective of this study was to describe country-specific lockdown measures and tuberculosis indicators collected during the first year of the COVID-19 pandemic. Data on lockdown/social restrictions (compulsory face masks and hand hygiene; international and local travel restrictions; restrictions to family visits, and school closures) were collected from 24 countries spanning five continents. The majority of the countries implemented multiple lockdowns with partial or full reopening. There was an overall decrease in active tuberculosis, drug-resistant tuberculosis, and latent tuberculosis cases. Although national lockdowns were effective in containing COVID-19 cases, several indicators of tuberculosis were affected during the pandemic.
- 30 April 2022
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 48 (2) , e20220087
Open AccessCountry-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study
The objective of this study was to describe country-specific lockdown measures and tuberculosis indicators collected during the first year of the COVID-19 pandemic. Data on lockdown/social restrictions (compulsory face masks and hand hygiene; international and local travel restrictions; restrictions to family visits, and school closures) were collected from 24 countries spanning five continents. The majority of the countries implemented multiple lockdowns with partial or full reopening. There was an overall decrease in active tuberculosis, drug-resistant tuberculosis, and latent tuberculosis cases. Although national lockdowns were effective in containing COVID-19 cases, several indicators of tuberculosis were affected during the pandemic.